© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

SRI

Top section

Top section

Missing mandates need not be so miserable

No one wins playing the blame game
US market remains the model as template issuance takes shape

Bitcoin ABS edges forward as price plunge turns collateral to cash

When loans' LTVs hit 80%, Bitcoin stakes are liquidated in seconds

Congo picked the best of an unappealing bunch of options

The yield was ultra high but Congo had little room to manoeuvre
US market remains the model as template issuance takes shape
Sub-sections
  • Yves Mersch, one of the ECB governing council’s staunchest hawks, has a new argument for why the central bank must abridge its purchase programmes: by keeping down the borrowing costs of the eurozone periphery, the ECB is helping countries to “circumvent EU loans”, which he thinks should not be allowed to happen.
  • Gland Pharma, a subsidiary of Chinese conglomerate Shanghai Fosun Pharmaceutical Group, has started bookbuilding for its Indian IPO, set to be the largest pharmaceutical listing in the country.
  • India’s Emcure Pharmaceuticals has returned to the loan market after four years, seeking a small amount of $34m.